Concomitant presence of p16/cyclin-dependent kinase 4 and cyclin D/cyclin-dependent kinase 4 complexes in LNCaP prostatic cancer cell line

Japanese Journal of Cancer Research

Volumn 88, Issue 3, 1997, Pages 229-233

  Itoh, Noriyuki ^a   Kakehi, Yoshiyuki ^a   Akao, Toshiya ^a   Kinoshita, Hidefumi ^a   Okada, Yusaku ^a   Yoshida, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cyclin dependent kinase 4; LNCaP; p16; Retinoblastoma protein

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER CELL CULTURE; ENZYME INHIBITOR COMPLEX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030935413     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00371.x     Document Type: Article

References (27)

1. Strauss, M., Lukas, J. and Bartek, J. Unrestricted cell cycling and cancer. Nat. Med., 1, 1245-1246 (1995).
2. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G. and Bartek, J. Retinoblastomaprotein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature, 375, 503-506 (1995).
3. Lukas, J., Aagaard, L., Strauss, M. and Bartek, J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res., 55, 4818-4823 (1995).
4. Aagaard, L., Lukas, J., Bartkova, J., Kjerulff, A. A., Strauss, M. and Bartek, J. Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer, 61, 115-120 (1995).
5. Lukas, J., Bartkova, J., Rohde, M., Strauss, M. and Bartek, J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol., 15, 2600-2611 (1995).
6. Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A. and Weinberg, R. A. Physical interaction of the retinoblastoma protein with human D cyclins. Cell, 73, 499-511 (1993).
7. Sherr, C. J. and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9, 1149-1163 (1995).
8. Tam, S. W., Theodoras, A. M., Shay, J. W., Draetta, G. F. and Pagano, M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene, 9, 2663-2674 (1994).
9. Kamb, A., Gruis, N. A., Weaver, F. J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day III, R. S., Johnson, B. E. and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
10. Serrano, M., Lee, H. W., Chin, L., Cordon-Cardo, C., Beach, D. and DePinho, R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996).
11. Habuchi, T., Takahashi, R., Yamada, H., Kakehi, Y., Sugiyama, T. and Yoshida, O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet, 342, 1087-1088 (1993).
12. Kinoshita, H., Yamada, H., Ogawa, O., Kakehi, Y., Osaka, M., Nakamura, E., Mishina, M., Habuchi, T., Takahashi, R., Sugiyama, T. and Yoshida, O. Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma. Jpn. J. Cancer Res., 86, 795-799 (1995).
13. Sherr, C. J. Mammalian G1 cyclins. Cell, 73, 1059-1065 (1993).
14. Bookstein, R., Shew, J. Y., Chen, P. L., Scully, P. and Lee, W. H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science, 247, 712-715 (1990).
15. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756 (1994).
16. Geradts, J., Kratzke, R. A., Niehans, G. A. and Lincoln, C. E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55, 6006-6011 (1995).
17. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O. and Reznikoff, C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55, 493-497 (1995).
18. Tam, S. W., Shay, J. W. and Pagano, M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res., 54, 5816-5820 (1994).
19. Draetta, G. F. Mammalian G1 cyclins. Curr. Opin. Cell. Biol., 6, 842-846 (1994).
20. Kara, E., Smith, R., Parry, D., Tahara, H., Stone, S. and Peters, G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol., 16, 859-867 (1996).
21. Hirai, H., Roussel, M. F., Kato, J. Y., Ashmun, R. A. and Sherr, C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol., 15, 2672-2681 (1995).
22. INK4/MTS1 tumour suppressor gene product. EMBO J., 14, 503-511 (1995).
23. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A. and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43, 1809-1818 (1983).
24. Esquenet, M., Swinnen, J. V., Heyns, W. and Verhoeven, G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenyl acetate. Prostate, 28, 182-194 (1996).
25. Israel, K., Sanders, B. G. and Kline, K. RRR-alphatocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr. Cancer, 24, 161-169 (1995).
26. Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Sensibar, J. A., Kim, J. H., Kalo, M. and Lee, C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta I in human prostatic cancer cells. Cancer Res., 56, 44-48 (1996).
27. Lin, M. F., DaVolio, J. and Garcia-Arenas, R. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells. Cancer Res., 52, 4600-4607 (1992).